---
title: U.S. IPO & Equity Capital Markets Brief
description: Two significant IPOs, Oura and Accelevation, are set to price this week, marking a pivotal moment in the market with substantial secondary supply and investor interest.
---

[blog](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y)

# [U.S. IPO & Equity Capital Markets Brief](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/u.s.-ipo-equity-capital-markets-brief)

 Written by [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) | Sep 28, 2026, 1:44:14 PM

**Period:** September 28–October 2, 2026  
**Coverage:** Traditional U.S. operating-company IPOs and consequential ECM transactions of at least $100 million

## 1. Executive Summary

Two qualifying IPOs are scheduled to price Tuesday and begin trading Wednesday: Oura and Accelevation Holdings. Together they represent approximately $2.76 billion of base proceeds at midpoint and make this the most consequential new-issue day since the summer window.

The books are constructive. Oura was heard approximately 3x covered before its Boston roadshow, while Accelevation was heard 3–4x covered as of Friday. Both deals are more than 70% secondary and carry large base floats, so final price sensitivity, share-count discipline and allocation quality matter more than the headline coverage multiples.

IPO Prophet® shows a 44 WARM Heat Index. ADARx’s strong financing and neutral first-day signal showed that even a well-covered book can produce a poor opening entry. Oura and Accelevation must prove demand remains after the first institutional rotation.

## 2. Active Qualifying IPO Calendar

| Issuer | Expected | Range | Shares / midpoint | Venue | Lead underwriters | IPO Prophet® rating |
| --- | --- | --- | --- | --- | --- | --- |
| Accelevation Holdings (ACCV) | Price Sept. 29; trade Sept. 30 | $20–$24 | 30.0M / $660M | Nasdaq | Morgan Stanley; J.P. Morgan | 7.90 / 10 |
| Oura (OURA) | Price Sept. 29; trade Sept. 30 | $40–$44 | 50.0M / $2.10B | Nasdaq | Goldman Sachs; Morgan Stanley; J.P. Morgan; Allen & Co.; Jefferies | Not publicly displayed |

No consequential non-IPO U.S. ECM transaction of at least $100 million with a firm execution date was identified at the cutoff.

## 3. Deal Analysis

### Oura (OURA)

**Terms and execution.**  Oura is offering 50.0 million shares at $40–$44, implying $2.10 billion at midpoint. Oura is selling 13.5 million shares and existing holders 36.5 million, making the base deal 73% secondary. Goldman Sachs, Morgan Stanley, J.P. Morgan, Allen & Co. and Jefferies are joint lead bookrunners. Nasdaq trading is expected September 30.

**Demand and book strength.**  The book was heard approximately 3x covered before the Boston roadshow. Eli Lilly has indicated interest in up to $100 million and Dragoneer in up to $300 million, roughly 19% of midpoint proceeds. The 50 million-share base means the deal is not scarce on share count alone.

**Float, FOMO and price discovery.**  Oura has the strongest brand recognition and clearest FOMO potential. The best setup is an intact deal priced at the top or above range, a controlled opening premium and a first pullback that holds well above issue. A large premium open could capitalize the scarcity narrative before trading begins.

**Key risks.**  The offering is seller-heavy, and most expected primary net proceeds are earmarked for tax obligations associated with employee equity awards. Valuation, hardware competition, consumer cyclicality, privacy concerns and subscription-growth durability are the main risks.

### Accelevation Holdings (ACCV)

**Terms and execution.**  Accelevation is offering 30.0 million shares at $20–$24, implying $660 million at midpoint. The company is offering 8.64 million shares and selling holders 21.36 million, making the base deal 71% secondary. Morgan Stanley and J.P. Morgan are joint lead bookrunners; Goldman Sachs, Barclays and BofA Securities are also joint bookrunners. Nasdaq trading is expected September 30. IPO Prophet® rates the deal 7.90 out of 10.

**Demand and book strength.**  The book was heard 3–4x covered as of Friday. Revenue reached approximately $437.5 million in the first half of 2026, net income was approximately $18.8 million and backlog was about $1.1 billion at June 30. Those figures support the AI-infrastructure growth case, but coverage must be tested against price sensitivity because most shares are sponsor supply.

**Float, scarcity and price discovery.**  Thirty million shares is meaningful supply, and the 4.5 million-share option is entirely secondary. The deal can still trade well if allocations concentrate with long-only investors seeking picks-and-shovels AI exposure, but it is not a low-float squeeze. A top-half price, intact shares and a stable opening auction would be more bullish than a large, fast premium that immediately fades.

**Key risks.**  Customer concentration, data-center capital-spending cyclicality, execution against backlog, leverage and sponsor monetization are the main constraints. The Up-C structure and debt-repayment use of primary proceeds also make valuation discipline important.

## 4. Underwriter and Market Structure Read-Through

Morgan Stanley and J.P. Morgan lead both transactions, while Goldman Sachs sits prominently on each syndicate. That concentration gives the banks a direct allocation and price-discovery challenge across $2.76 billion of midpoint supply on the same trading day.

Both deals combine strong demand narratives with heavy secondary supply. Oura offers brand and subscription momentum; Accelevation offers AI-infrastructure growth and backlog. In each case, the sellers are testing how much thematic demand can absorb without an issuer-friendly concession.

The window will be healthier if both deals price with intact share counts and hold above issue through the close. A strong open followed by a low close would repeat the ADARx lesson: good financing execution does not guarantee a good issuance-day trade.

## 5. IPO Prophet® Read-Through

For Oura, the 3x coverage indication and $400 million of cornerstone interest support the book, but the 50 million-share float and 73% secondary mix cap pure scarcity. A Bull signal should require evidence that opening demand exceeds the supply already reflected in a potentially aggressive first print.

For Accelevation, the 7.90 rating and 3–4x coverage indicate a constructive setup, but the 71% secondary mix raises the bar for allocation quality. The AI theme can create momentum, yet a durable move needs intact terms, limited price sensitivity and a first pullback that holds.

Across both deals, the framework remains unchanged: measure tradable float against institutional demand, distinguish FOMO from durable sponsorship, and do not treat an opening premium as bullish unless the post-open tape confirms it.

## 6. Q3 Close and Q4 ECM Watchlist

Every issuer below has a current public S-1 or F-1 on file. TFP Group is added following its September 25 public F-1. Accelevation and Oura have live terms; Bamboo and Holtec remain publicly filed but postponed; SB Energy remains publicly filed despite delayed timing.

| Issuer | Verified filing status | Terms / venue | IPO Prophet® focus |
| --- | --- | --- | --- |
| Accelevation Holdings (ACCV) | Public S-1; Sept. 22 amendment sets terms | $20–$24; 30.0M; Nasdaq; Sept. 30 | AI demand, 71% secondary supply, leverage, backlog and opening support |
| Oura (OURA) | Public S-1; Sept. 21 amendment sets terms | $40–$44; 50.0M; Nasdaq; Sept. 30 | Brand/FOMO, 73% secondary supply, valuation, anchors and float |
| Bamboo Insurance (BMB) | Public S-1; postponed Sept. 22 | Formerly $18–$20; 35.0M; NYSE | Relaunch timing, seller supply, catastrophe exposure and valuation |
| Holtec Nuclear (HNUC) | Public S-1; postponed | Formerly $15–$18; 50.0M; Nasdaq / Nasdaq Texas | Relaunch timing, nuclear theme, valuation and large-float execution |
| Aggreko (AGKO) | Public F-1 filed Aug. 24 | Terms pending; NYSE | Power-demand theme, leverage, valuation and supply mix |
| City Therapeutics (CTY) | Public S-1 filed Sept. 24 | Terms pending; Nasdaq | $100M placeholder; RNAi platform, clinical risk, sponsorship and float |
| CoVolt Power (KVLT) | Public S-1 filed Aug. 21 | Terms pending; NYSE | Backlog quality, execution risk, float and valuation |
| Cumberland Farms (CMBY) | Public F-1; amended Sept. 3 | Terms pending | Defensive demand, leverage, deal size and float construction |
| Entrata (ENT) | Public S-1 filed May 28 | Terms pending; NYSE | Software growth, profitability, crossover support and float |
| Genneia (GENN) | Public F-1 filed July 2 | Terms pending | Argentina risk, power exposure, valuation and U.S. demand |
| Iambic Therapeutics (IAM) | Public S-1 filed Sept. 21 | Terms pending; Nasdaq | $100M placeholder; AI-biotech narrative, clinical risk and crossover demand |
| Nscale (NSCL) | Public F-1 filed Sept. 18 | Terms pending | AI infrastructure, capital intensity, customer concentration and supply |
| Retension Pharmaceuticals (RTSN) | Public S-1 filed Sept. 18 | Terms pending | Clinical-stage biotech; crossover support, cash runway and scarcity |
| SB Energy (SBE) | Public S-1 filed Sept. 1; timing delayed | Terms pending; Nasdaq / Nasdaq Texas | Valuation, customer concentration, capital intensity and execution |
| Syntiant (SYTN) | Public S-1; amended Aug. 31 | Terms pending | Edge-AI demand, semiconductor cyclicality and scarcity |
| Tailored Brands (MENW) | Public S-1 filed July 10 | Terms pending | Sponsor exit, leverage, consumer demand and valuation |
| TFP Group (TFP) | Public F-1 filed Sept. 25 | Terms pending; Nasdaq intended | $100M placeholder; insurance distribution, sponsor supply and valuation |
| The Wella Company (WELA) | Public S-1 filed Aug. 31 | Terms pending; NYSE | Sponsor exit, leverage, consumer demand and seller supply |
| TRex Bio (TRXB) | Public S-1 filed Sept. 18 | Terms pending | Clinical concentration, specialist sponsorship and float |
| YPF Energía Eléctrica (YLUZ) | Public F-1; amended July 23 | Terms pending; NYSE intended | Argentina risk, selling-holder supply and U.S. demand |

## 7. Confidential and Unfiled Pipeline

Anthropic is explicitly classified as a confidential submission because no public registration statement is available; its expected timing has shifted to Q4. Altera is separately classified as an unfiled pipeline candidate. Neither is described as a public S-1 issuer.

| Issuer | Classification | Reported timing | Read-through |
| --- | --- | --- | --- |
| Anthropic | Confidential SEC submission; no public S-1 | Q4; mid-October at earliest | Major AI valuation test; monitor float, mix, price sensitivity and opening FOMO |
| Altera | Unfiled pipeline candidate | Potential 2026 IPO; no public filing or terms | Large semiconductor candidate; reported preparation is not an SEC filing |

[View full post](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/u.s.-ipo-equity-capital-markets-brief)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Eric Friedman"
  },
  "dateModified" : "2026-09-28T13:44:14.492Z",
  "datePublished" : "2026-09-28T13:44:14Z",
  "headline" : "U.S. IPO & Equity Capital Markets Brief",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1024,
    "url" : "https://43826620.fs1.hubspotusercontent-na1.net/hubfs/43826620/AI-Generated%20Media/Images/Financial%20District%20Skyline%20With%20Digital%20Billboard%20At%20Morning.png",
    "width" : 1536
  },
  "mainEntityOfPage" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/u.s.-ipo-equity-capital-markets-brief",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "blog"
  }
}
```